{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:03:25Z","timestamp":1793113405216,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s40119-021-00233-7","type":"journal-article","created":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:02:56Z","timestamp":1626048176000},"page":"397-406","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4925-7985","authenticated-orcid":false,"given":"Fabio","family":"Angeli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Verdecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpaolo","family":"Reboldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,12]]},"reference":[{"key":"233_CR1","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1161\/01.HYP.28.4.652","volume":"28","author":"S Ergul","year":"1996","unstructured":"Ergul S, Parish DC, Puett D, Ergul A. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension. 1996;28:652\u20135.","journal-title":"Hypertension"},{"key":"233_CR2","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1097\/00004872-199816121-00007","volume":"16","author":"EL Schiffrin","year":"1998","unstructured":"Schiffrin EL. Endothelin and endothelin antagonists in hypertension. J Hypertens. 1998;16:1891\u20135.","journal-title":"J Hypertens"},{"key":"233_CR3","first-page":"199","volume":"31","author":"EL Schiffrin","year":"1998","unstructured":"Schiffrin EL. Endothelin: role in hypertension. Biol Res. 1998;31:199\u2013208.","journal-title":"Biol Res"},{"key":"233_CR4","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1124\/jpet.118.253864","volume":"368","author":"F Trensz","year":"2019","unstructured":"Trensz F, Bortolamiol C, Kramberg M, et al. Pharmacological characterization of aprocitentan, a dual endothelin receptor antagonist, alone and in combination with blockers of the renin angiotensin system, in two models of experimental hypertension. J Pharmacol Exp Ther. 2019;368:462\u201373.","journal-title":"J Pharmacol Exp Ther"},{"key":"233_CR5","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1124\/jpet.108.142976","volume":"327","author":"M Iglarz","year":"2008","unstructured":"Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther. 2008;327:736\u201345.","journal-title":"J Pharmacol Exp Ther"},{"key":"233_CR6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s13318-019-00590-8","volume":"45","author":"PN Sidharta","year":"2020","unstructured":"Sidharta PN, Dingemanse J. Effect of multiple-dose aprocitentan administration on the pharmacokinetics of midazolam in healthy male subjects. Eur J Drug Metab Pharmacokinet. 2020;45:227\u201334.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"233_CR7","doi-asserted-by":"publisher","first-page":"949","DOI":"10.2147\/DDDT.S199051","volume":"13","author":"PN Sidharta","year":"2019","unstructured":"Sidharta PN, Melchior M, Kankam MK, Dingemanse J. Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects. Drug Des Dev Ther. 2019;13:949\u201364.","journal-title":"Drug Des Dev Ther"},{"key":"233_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1472-6947-5-8","volume":"5","author":"RB Haynes","year":"2005","unstructured":"Haynes RB, Kastner M, Wilczynski NL, Hedges T. Developing optimal search strategies for detecting clinically sound and relevant causation studies in embase. BMC Med Inform Decis Mak. 2005;5:8.","journal-title":"BMC Med Inform Decis Mak"},{"key":"233_CR9","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/S0140-6736(00)02786-0","volume":"356","author":"L McAuley","year":"2000","unstructured":"McAuley L, Pham B, Tugwell P, Moher D. Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses? Lancet. 2000;356:1228\u201331.","journal-title":"Lancet"},{"key":"233_CR10","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1136\/hrt.2004.053991","volume":"91","author":"T Attina","year":"2005","unstructured":"Attina T, Camidge R, Newby DE, Webb DJ. Endothelin antagonism in pulmonary hypertension, heart failure, and beyond. Heart. 2005;91:825\u201331.","journal-title":"Heart"},{"key":"233_CR11","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11906-013-0380-1","volume":"15","author":"RC Moorhouse","year":"2013","unstructured":"Moorhouse RC, Webb DJ, Kluth DC, Dhaun N. Endothelin antagonism and its role in the treatment of hypertension. Curr Hypertens Rep. 2013;15:489\u201396.","journal-title":"Curr Hypertens Rep"},{"key":"233_CR12","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1161\/01.CIR.103.25.3129","volume":"103","author":"F Ruschitzka","year":"2001","unstructured":"Ruschitzka F, Quaschning T, Noll G, et al. Endothelin 1 type a receptor antagonism prevents vascular dysfunction and hypertension induced by 11beta-hydroxysteroid dehydrogenase inhibition: role of nitric oxide. Circulation. 2001;103:3129\u201335.","journal-title":"Circulation"},{"key":"233_CR13","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1139\/y96-085","volume":"74","author":"AM Sharifi","year":"1996","unstructured":"Sharifi AM, Schiffrin EL. Endothelin receptors mediating vasoconstriction in rat pressurized small arteries. Can J Physiol Pharmacol. 1996;74:934\u20139.","journal-title":"Can J Physiol Pharmacol"},{"key":"233_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/00004872-199715010-00005","volume":"15","author":"EL Schiffrin","year":"1997","unstructured":"Schiffrin EL, Deng LY, Sventek P, Day R. Enhanced expression of endothelin-1 gene in resistance arteries in severe human essential hypertension. J Hypertens. 1997;15:57\u201363.","journal-title":"J Hypertens"},{"key":"233_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1159\/000159151","volume":"33","author":"EL Schiffrin","year":"1996","unstructured":"Schiffrin EL, Lariviere R, Li JS, Sventek P. Enhanced expression of the endothelin-1 gene in blood vessels of doca-salt hypertensive rats: correlation with vascular structure. J Vasc Res. 1996;33:235\u201348.","journal-title":"J Vasc Res"},{"issue":"Suppl 3","key":"233_CR16","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1097\/00005344-199526003-00003","volume":"26","author":"EL Schiffrin","year":"1995","unstructured":"Schiffrin EL, Lariviere R, Li JS, Sventek P, Touyz RM. Enhanced expression of endothelin-1 gene may cause blood pressure-independent vascular hypertrophy. J Cardiovasc Pharmacol. 1995;26(Suppl 3):S5-8.","journal-title":"J Cardiovasc Pharmacol"},{"key":"233_CR17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/332411a0","volume":"332","author":"M Yanagisawa","year":"1988","unstructured":"Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411\u20135.","journal-title":"Nature"},{"key":"233_CR18","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/MNH.0b013e32834f0092","volume":"21","author":"Y Rautureau","year":"2012","unstructured":"Rautureau Y, Schiffrin EL. Endothelin in hypertension: an update. Curr Opin Nephrol Hypertens. 2012;21:128\u201336.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"233_CR19","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1042\/CS20100222","volume":"119","author":"M Iglarz","year":"2010","unstructured":"Iglarz M, Clozel M. At the heart of tissue: endothelin system and end-organ damage. Clin Sci. 2010;119:453\u201363.","journal-title":"Clin Sci"},{"key":"233_CR20","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jacc.2008.12.050","volume":"53","author":"E Belaidi","year":"2009","unstructured":"Belaidi E, Joyeux-Faure M, Ribuot C, Launois SH, Levy P, Godin-Ribuot D. Major role for hypoxia inducible factor-1 and the endothelin system in promoting myocardial infarction and hypertension in an animal model of obstructive sleep apnea. J Am Coll Cardiol. 2009;53:1309\u201317.","journal-title":"J Am Coll Cardiol"},{"key":"233_CR21","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.lfs.2012.03.032","volume":"91","author":"S Sen","year":"2012","unstructured":"Sen S, Chen S, Feng B, Iglarz M, Chakrabarti S. Renal, retinal and cardiac changes in type 2 diabetes are attenuated by macitentan, a dual endothelin receptor antagonist. Life Sci. 2012;91:658\u201368.","journal-title":"Life Sci"},{"key":"233_CR22","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/MNH.0b013e32833a7a25","volume":"19","author":"R Moore","year":"2010","unstructured":"Moore R, Linas S. Endothelin antagonists and resistant hypertension in chronic kidney disease. Curr Opin Nephrol Hypertens. 2010;19:432\u20136.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"233_CR23","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/cpt.2043","volume":"109","author":"P Gueneau de Mussy","year":"2020","unstructured":"Gueneau de Mussy P, Sidharta PN, Wuerzner G, et al. Effects of the dual endothelin receptor antagonist aprocitentan on body weight and fluid homeostasis in healthy subjects on a high sodium diet. Clin Pharmacol Ther. 2020;109:746\u201353.","journal-title":"Clin Pharmacol Ther"},{"key":"233_CR24","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1161\/01.HYP.33.2.753","volume":"33","author":"C Cardillo","year":"1999","unstructured":"Cardillo C, Kilcoyne CM, Waclawiw M, Cannon RO 3rd, Panza JA. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension. 1999;33:753\u20138.","journal-title":"Hypertension"},{"key":"233_CR25","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1056\/NEJM199803193381202","volume":"338","author":"H Krum","year":"1998","unstructured":"Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan hypertension investigators. N Engl J Med. 1998;338:784\u201390.","journal-title":"N Engl J Med"},{"key":"233_CR26","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/j.1524-6175.2007.07244.x","volume":"9","author":"HR Black","year":"2007","unstructured":"Black HR, Bakris GL, Weber MA, et al. Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich). 2007;9:760\u20139.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"233_CR27","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(09)61500-2","volume":"374","author":"MA Weber","year":"2009","unstructured":"Weber MA, Black H, Bakris G, et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:1423\u201331.","journal-title":"Lancet"},{"key":"233_CR28","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1161\/HYPERTENSIONAHA.110.156976","volume":"56","author":"GL Bakris","year":"2010","unstructured":"Bakris GL, Lindholm LH, Black HR, et al. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension. 2010;56:824\u201330.","journal-title":"Hypertension"},{"key":"233_CR29","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s40261-019-00837-x","volume":"39","author":"PN Sidharta","year":"2019","unstructured":"Sidharta PN, Ulc I, Dingemanse J. Single-dose pharmacokinetics and tolerability of aprocitentan, a dual endothelin receptor antagonist, in subjects with severe renal function impairment. Clin Drug Investig. 2019;39:1117\u201323.","journal-title":"Clin Drug Investig"},{"key":"233_CR30","doi-asserted-by":"crossref","unstructured":"Fontes MSC, Dingemanse J, Sidharta PN. Multiple-dose pharmacokinetics, safety, and tolerability of aprocitentan, a dual endothelin receptor antagonist, in healthy Japanese and Caucasian subjects. Clin Pharmacol Drug Dev 2020. https:\/\/doi.org\/10.1002\/cpdd.881.","DOI":"10.1002\/cpdd.881"},{"key":"233_CR31","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1002\/cpdd.815","volume":"9","author":"PN Sidharta","year":"2020","unstructured":"Sidharta PN, Dingemanse J. Effects of multiple-dose administration of aprocitentan on the pharmacokinetics of rosuvastatin. Clin Pharmacol Drug Dev. 2020;9:995\u20131002.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"233_CR32","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1161\/HYPERTENSIONAHA.119.14504","volume":"75","author":"P Verweij","year":"2020","unstructured":"Verweij P, Danaietash P, Flamion B, Menard J, Bellet M. Randomized dose-response study of the new dual endothelin receptor antagonist aprocitentan in hypertension. Hypertension. 2020;75:956\u201365.","journal-title":"Hypertension"},{"key":"233_CR33","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1161\/01.CIR.0000144462.08345.B9","volume":"110","author":"F Amiri","year":"2004","unstructured":"Amiri F, Virdis A, Neves MF, et al. Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation. 2004;110:2233\u201340.","journal-title":"Circulation"},{"key":"233_CR34","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1161\/HYPERTENSIONAHA.108.117366","volume":"52","author":"N Dhaun","year":"2008","unstructured":"Dhaun N, Goddard J, Kohan DE, Pollock DM, Schiffrin EL, Webb DJ. Role of endothelin-1 in clinical hypertension: 20 years on. Hypertension. 2008;52:452\u20139.","journal-title":"Hypertension"},{"key":"233_CR35","doi-asserted-by":"publisher","first-page":"14367","DOI":"10.1073\/pnas.95.24.14367","volume":"95","author":"M Barton","year":"1998","unstructured":"Barton M, Haudenschild CC, d\u2019Uscio LV, Shaw S, Munter K, Luscher TF. Endothelin ETA receptor blockade restores no-mediated endothelial function and inhibits atherosclerosis in apolipoprotein e-deficient mice. Proc Natl Acad Sci USA. 1998;95:14367\u201372.","journal-title":"Proc Natl Acad Sci USA"},{"key":"233_CR36","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0008-6363(00)00083-3","volume":"47","author":"J Bauersachs","year":"2000","unstructured":"Bauersachs J, Fraccarollo D, Galuppo P, Widder J, Ertl G. Endothelin-receptor blockade improves endothelial vasomotor dysfunction in heart failure. Cardiovasc Res. 2000;47:142\u20139.","journal-title":"Cardiovasc Res"},{"key":"233_CR37","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1161\/01.CIR.99.13.1747","volume":"99","author":"PJ Best","year":"1999","unstructured":"Best PJ, McKenna CJ, Hasdai D, Holmes DR Jr, Lerman A. Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolemia. Circulation. 1999;99:1747\u201352.","journal-title":"Circulation"},{"key":"233_CR38","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/bcp.12064","volume":"76","author":"DE Kohan","year":"2013","unstructured":"Kohan DE, Pollock DM. Endothelin antagonists for diabetic and non-diabetic chronic kidney disease. Br J Clin Pharmacol. 2013;76:573\u20139.","journal-title":"Br J Clin Pharmacol"},{"key":"233_CR39","first-page":"817","volume":"17","author":"F Angeli","year":"2004","unstructured":"Angeli F, Verdecchia P, Reboldi GP, et al. Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects. Am J Hypertens. 2004;17:817\u201322.","journal-title":"Am J Hypertens"},{"key":"233_CR40","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.amjcard.2003.09.052","volume":"93","author":"F Angeli","year":"2004","unstructured":"Angeli F, Verdecchia P, Reboldi GP, et al. Meta-analysis of effectiveness or lack thereof of angiotensin-converting enzyme inhibitors for prevention of heart failure in patients with systemic hypertension. Am J Cardiol. 2004;93:240\u20133.","journal-title":"Am J Cardiol"},{"key":"233_CR41","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1097\/HJH.0b013e328306ebe2","volume":"26","author":"G Reboldi","year":"2008","unstructured":"Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens. 2008;26:1282\u20139.","journal-title":"J Hypertens"},{"key":"233_CR42","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1097\/HJH.0b013e3283469976","volume":"29","author":"G Reboldi","year":"2011","unstructured":"Reboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, Verdecchia P. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens. 2011;29:1253\u201369.","journal-title":"J Hypertens"},{"key":"233_CR43","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1093\/eurheartj\/ehn575","volume":"30","author":"P Verdecchia","year":"2009","unstructured":"Verdecchia P, Angeli F, Cavallini C, et al. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. Eur Heart J. 2009;30:679\u201388.","journal-title":"Eur Heart J"},{"key":"233_CR44","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41371-018-0081-y","volume":"32","author":"F Angeli","year":"2018","unstructured":"Angeli F, Gentile G, Trapasso M, Verdecchia P, Reboldi G. Role and prognostic value of individual ambulatory blood pressure components in chronic kidney disease. J Hum Hypertens. 2018;32:625\u201332.","journal-title":"J Hum Hypertens"},{"key":"233_CR45","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1586\/14779072.2014.903155","volume":"12","author":"F Angeli","year":"2014","unstructured":"Angeli F, Reboldi G, Poltronieri C, et al. Clinical utility of ambulatory blood pressure monitoring in the management of hypertension. Expert Rev Cardiovasc Ther. 2014;12:623\u201334.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"233_CR46","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/HJH.0000000000000497","volume":"33","author":"F Angeli","year":"2015","unstructured":"Angeli F, Reboldi G, Verdecchia P. Interpretation of ambulatory blood pressure profile: a prognostic approach for clinical practice. J Hypertens. 2015;33:454\u20137.","journal-title":"J Hypertens"},{"key":"233_CR47","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.numecd.2014.04.004","volume":"24","author":"F Angeli","year":"2014","unstructured":"Angeli F, Verdecchia P, Poltronieri C, et al. Ambulatory blood pressure monitoring in the elderly: features and perspectives. Nutr Metab Cardiovasc Dis. 2014;24:1052\u20136.","journal-title":"Nutr Metab Cardiovasc Dis"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-021-00233-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-021-00233-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-021-00233-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T17:36:19Z","timestamp":1699205779000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-021-00233-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,12]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["233"],"URL":"https:\/\/doi.org\/10.1007\/s40119-021-00233-7","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,12]]},"assertion":[{"value":"26 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}